



Date 14-02-2025

**The General Manager
Department of Corporate Services – CRD
BSE LIMITED PhirozeJeejeebhoy Towers
DalalStreet,Mumbai 400 001.**

Ref:- Scrip Code : 526139

Subject: **Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024**

Dear Sir/Madam,

Pursuant to the Securities and Exchange Board of India Circular dated December 31, 2024, please find attached the Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024,

We kindly request you to take the above said on record.

Thanking You,

Yours faithfully
For TRANSGENE BIOTEK LIMITED

DR K KOTESWARA RAO
MANAGING DIRECTOR



FORMAT FOR QUARTERLY INTEGRATED FILING (FINANCIAL)

- A. FINANCIAL RESULTS: Attached as Annexure — A.
- B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.: **NOT APPLICABLE**
- C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES: **NOT APPLICABLE AS THERE IS NO DEFAULT**
- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter): **NOT APPLICABLE**
- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (**applicable only for Annual Filing i.e., 4th quarter**): **NOT APPLICABLE.**

Limited Review report

To
The Board of Directors,
M/s TRANSGENE BIOTEK LIMITED
Hyderabad

We have reviewed the accompanying statement of unaudited standalone financial results of M/s TRANSGENE BIOTEK LIMITED for the Quarter ended 31st December 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VASAVI & CO,
Chartered Accountants
FRN 020965S

G.R.L. Vasavi

(CA VASAVI GOLLAPUDI)
Proprietor
MRN 249259



UDIN for this document is: 25249259BMOPYQ6168

Place: Hyderabad

Date: 24/01/2025



M/S VASAVI & CO

Chartered Accountants

Independent Auditor's Review Report On consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
M/s Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of M/s Transgene Biotek Ltd ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associates for the quarter ended 31/12/2024 being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31/12/2024 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

5. The Statement includes the results of the following entities:

1. Transgene Biotek HK Ltd - Subsidiary

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. We did not review the interim financial results of subsidiary included in the Statement, whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 31 December 2024, as considered in the consolidated unaudited financial results.

**For VASAVI & CO,
Chartered Accountants
FRN 020965S**

G.R.L. Vasavi

**(CA VASAVI GOLLAPUDI)
Proprietor
MRN 249259**



UDIN for this document is: 25249259BMOPYQ6168

**Place: Hyderabad
Date: 24/01/2025**



TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2024

(In Lakhs)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended	Year Ended
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Audited)	31.12.2024 (Unaudited)	31.03.2024 (Audited)
1	Revenue from operations	7.65	5.85	4.50	18.42	23.49
2	Other income (net)	4.38	4.38	4.38	73.96	18.27
3	Total income (1 + 2)	12.03	10.23	8.88	92.39	41.76
4	EXPENSES					
	Cost of materials consumed	0.00	0.00	0.01	0.00	0.06
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	8.15	8.19	7.66	24.44	31.12
	Finance costs	1.73	1.73	3.23	5.18	12.91
	Depreciation and amortisation expense	2.32	2.32	2.31	6.97	9.23
	Other expenses	8.73	5.33	7.58	52.10	53.97
	Total expenses	20.93	17.57	20.80	88.68	107.30
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	-8.90	-7.34	-11.91	3.70	-65.55
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00
7	Profit before tax (5 - 6)	-8.90	-7.34	-11.91	3.70	-65.55
8	Tax expense					
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00
	Total tax expense	0.00	0.00	0.00	0.00	0.00
9	Profit for the year (7 - 8)	-8.90	-7.34	-11.91	3.70	-65.55
10	Other comprehensive income					
	A Items that will not be reclassified subsequently to profit or loss					
	(a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	0.00	0.00	0.00	0.00
11	Total comprehensive income for the year (9 + 10)	-8.90	-7.34	-11.91	3.70	-65.55
12	Earnings per equity share					
	(Equity shares, par value of Rs. 10 each)	757.70	757.70	757.70	757.70	757.70
	Basic (Rs.)	(0.01)	(0.01)	(0.02)	0.00	(0.09)
	Diluted (Rs.)	(0.01)	(0.01)	(0.02)	0.00	(0.09)

Notes:

- 1 We received inputs through NidFree that the academic human clinical Studies on Oral Insulin are progressing as planned.
- 2 As informed at the last board meeting, the management continues to explore the possibility to raise required funds to clear BIRAC and other dues.
- 3 Next date for SAT hearing is scheduled for 24th February 2025.
- 4 The company received Adjudication Order from the Enforcement Directorate, Southern Regional Office, Chennai on 30th December 2024 imposing a monetary penalty of Rs. 203.02 Crs in total under alleged contraventions and regulations of Foreign Management Act, 2000, relating to the GDR issue. The management has initiated steps to appeal against this order through the available judiciary channels.
- 5 No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0.
- 6 The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors at their meeting held on 24th January 2025.

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 24/01/2025
Place:Hyderabad

TRANSGENE BIOTEK LIMITED

Notes forming part of the Standalone financial statements

Other expenses		(In Lakhs)
Particulars		For the Period ended December 2024
BSNL Fiber net		0.04
Conveyance Expenses		0.37
Directors sitting fee		0.15
Legal and Professional Charges		6.87
Miscellaneous Expenses		0.02
Office Expenses		-0.53
Postage and Courier Expenses		0.00
Telephone Expenses		0.02
Website and Software		0.43
Advertisement		0.22
Business promotional exp		0.09
Interest and penalties		0.00
Bank charges		0.00
Total		7.67

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 24/01/2025

Place:Hyderabad



TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2024

(In Lakhs)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended	Year Ended
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Audited)	31.12.2024 (Unaudited)	31.03.2024 (Audited)
1	Revenue from operations	7.65	5.85	4.50	18.42	23.49
2	Other income (net)	4.38	4.38	4.38	73.96	18.27
3	Total income (1 + 2)	12.03	10.23	8.88	92.39	41.76
4	EXPENSES					
	Cost of materials consumed	0.00	0.00	0.01	0.00	0.06
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	8.15	8.19	7.66	24.44	31.12
	Finance costs	1.73	1.73	3.23	5.18	12.91
	Depreciation and amortisation expense	2.32	2.32	2.31	6.97	9.23
	Other expenses	8.73	5.33	7.58	52.10	53.97
	Total expenses	20.93	17.57	20.80	88.68	107.30
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	-8.90	-7.34	-11.91	3.70	-65.55
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00
7	Profit before tax (5 - 6)	-8.90	-7.34	-11.91	3.70	-65.55
8	Tax expense					
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00
	Total tax expense	0.00	0.00	0.00	0.00	0.00
9	Profit for the year (7 - 8)	-8.90	-7.34	-11.91	3.70	-65.55
10	Other comprehensive income					
	A Items that will not be reclassified subsequently to profit or loss					
	(a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	0.00	0.00	0.00	0.00
11	Total comprehensive income for the year (9 + 10)	-8.90	-7.34	-11.91	3.70	-65.55
12	Earnings per equity share					
	(Equity shares, par value of Rs. 10 each)					
	Basic (Rs.)	757.70	757.70	757.70	757.70	757.70
	Diluted (Rs.)	(0.01)	(0.01)	(0.02)	0.00	(0.09)
		(0.01)	(0.01)	(0.02)	0.00	(0.09)

Notes:

- 1 We received inputs through NidFree that the academic human clinical Studies on Oral Insulin are progressing as planned.
- 2 As informed at the last board meeting, the management continues to explore the possibility to raise required funds to clear BIRAC and other dues.
- 3 Next date for SAT hearing is scheduled for 24th February 2025.
- 4 The company received Adjudication Order from the Enforcement Directorate, Southern Regional Office, Chennai on 30th December 2024 imposing a monetary penalty of Rs. 203.02 Crs in total under alleged contraventions and regulations of Foreign Management Act, 2000, relating to the GDR issue. The management has initiated steps to appeal against this order through the available judiciary channels.
- 5 No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0.
- 6 The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors at their meeting held on 24th January 2025.

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 24/01/2025

Place:Hyderabad

TRANSGENE BIOTEK LIMITED

Notes forming part of the Consolidated financial statements

Other expenses (In Lakhs)

Particulars	For the Period ended December 2024
BSNL Fiber net	0.04
Conveyance Expenses	0.37
Directors sitting fee	0.15
Legal and Professional Charges	6.87
Miscellaneous Expenses	0.02
Office Expenses	-0.53
Postage and Courier Expenses	0.00
Telephone Expenses	0.02
Website and Software	0.43
Advertisement	0.22
Business promotional exp	0.09
Interest and penalties	0.00
Bank charges	0.00
Total	7.67

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 24/01/2025

Place:Hyderabad